SEC Comment Letter for Galmed Pharmaceuticals Ltd. (GLMD) (CIK 0001595353) (EOCN) — Apr 2, 2018
Galmed Pharmaceuticals Ltd. (GLMD) (CIK 0001595353)
Date: April 2, 2018 · CIK: 0001595353 · Accession: 0000000000-18-009868
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-223923
Letter
April 2, 2018 Allen Baharaff President and Chief Executive Officer Galmed Pharmaceuticals Ltd. 16 Tiomkin St. Tel Aviv, Israel 6578317 Re:Galmed Pharmaceuticals Ltd. Registration Statement on Form F-3 Filed March 26, 2018 File No. 333-223923 Dear Mr. Baharaff: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Christine Westbrook at (202) 551-5019 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Gary Emmanuel, Esq.
Show Raw Text
April 2, 2018
Allen Baharaff
President and Chief Executive Officer
Galmed Pharmaceuticals Ltd.
16 Tiomkin St.
Tel Aviv, Israel 6578317
Re:Galmed Pharmaceuticals Ltd.
Registration Statement on Form F-3
Filed March 26, 2018
File No. 333-223923
Dear Mr. Baharaff:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Christine Westbrook at (202) 551-5019 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Gary Emmanuel, Esq.